MedTrace Logo

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.

Conditions

  • Spasticity

Interventions

BIOLOGICAL

IPN10200

Powder and solvent for solution for injection

DRUG

Placebo

Powder and solvent for solution for injection

BIOLOGICAL

Dysport

Powder for solution for injection

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2029-03-30
Completion
2029-03-30
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Bulgaria
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Japan
  • Poland
  • Portugal
  • Russia
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752774 on ClinicalTrials.gov